The right dose of daunorubicin(DNR)for the treatment of newly diagnosed acute myeloid leukemia(AML)is uncertain.Previous trials have shown conflicting results concerning the efficacy of high or low doses of daunorubicin to induction chemotherapy for newly diagnosed AML.A systematic review and meta-analysis was conducted to resolve this controversial issue.